Dexcom CEO Jake Leach on 2026 Outlook, GLP-1s, and CGM Growth

Dexcom's Growth Outlook and Strategy

• 🚀 Dexcom is guiding for significant growth, aiming to impact diabetes and metabolic health globally.
• 💡 The company plans to achieve this through new innovations that advance the glucose sensing category and by generating clinical evidence to expand access and coverage.

The Synergy of CGM and GLP-1s

• 🎯 Continuous Glucose Monitoring (CGM) is a fast-growing medtech category, with only 2% penetration among people with diabetes.
• 🤝 GLP-1s are seen as a complementary pharmaceutical innovation to CGM.
• 📈 CGM provides users with immediate feedback on glucose levels and how lifestyle factors impact them, while GLP-1s aid digestive control and insulin sensitivity.
• ✅ Combining CGM's data with GLP-1 therapy allows users to tailor behaviors for optimized glucose control and enhances adherence to GLP-1 therapy.

Expanding Coverage and Access

• 🏥 Dexcom has focused on driving coverage and reimbursement for its technology for the past decade.
• 🌟 A major expansion occurred last year when many private insurance companies began covering CGM for anybody with diabetes, not just insulin users.
• 🌍 Currently, 9 million people in the U.S. have coverage for CGM but are not yet using it, indicating significant untapped potential.
• 🌐 Dexcom anticipates continued coverage growth in the U.S. and internationally, including Western Europe and Asia Pacific regions.

User Growth and Future Prospects

• 📊 Dexcom exited 2025 with approximately 3.5 million active users globally, representing over 20% growth from 2024.
• 📈 The company experienced a record number of new patients in 2025 and anticipates strong new patient growth in 2026.